A pharmacokinetic and pharmacodynamic study of pioglitazone in a model of induced insulin resistance in normal horses

@inproceedings{Wearn2010APA,
  title={A pharmacokinetic and pharmacodynamic study of pioglitazone in a model of induced insulin resistance in normal horses},
  author={Jamie Macquarie Wearn},
  year={2010}
}
Equine Metabolic Syndrome (EMS) is a unique condition of horses characterized by adiposity, insulin resistance, and an increased risk of laminitis. Reducing insulin resistance may decrease the incidence of laminitis in horses with EMS. Pioglitazone, a thiazolidinedione class of anti-diabetic drug, has proven efficacy in humans with type 2 diabetes, a syndrome of insulin resistance sharing some similarities with EMS. The ability of pioglitazone to influence insulin sensitivity in an endotoxin… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Equine metabolic syndrome.

  • The Veterinary clinics of North America. Equine practice
  • 2011

Oral dose 45 mg single dose 45 mg multiple dose 45 mg single dose 15 mg single dose

Kalliokoski
  • 2008